Pro-Dex saw its IBD SmartSelect Composite Rating rise to 96 Tuesday, up from 88 the day before.
The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. The best stocks tend to have a 95 or better grade as they kick off a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.
Pro-Dex is now out of buy range after breaking out from a 22.99 entry in a cup without handle. Be aware that it is a thinly traded stock, with average daily dollar volume under $8 million.
Lean How — And When — To Sell Stocks
One weak spot is the company's 75 EPS Rating, which tracks quarterly and annual earnings growth. Look for that to improve to 80 or better to show it's in the top 20% of all stocks.
Its Accumulation/Distribution Rating of A shows heavy buying by institutional investors, such as mutual funds and pension funds, over the last 13 weeks.
In Q1, the company reported 0% earnings growth. Revenue growth fell to 25%, down from 41% in the previous quarter.
Pro-Dex holds the No. 4 rank among its peers in the Medical-Products industry group. LeMaitre Vascular is the top-ranked stock within the group.
